ophthalmologytimes2d
ANI Pharmaceuticals completes acquisition of Alimera Sciences
The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with ...
Business Insider3d
ANI Pharmaceuticals’ Acquisition of Alimera Sciences Bolsters Buy Rating and $94 Target Price
Oren Livnat has given his Buy rating due to a combination of factors including the recent acquisition of Alimera Sciences by ANI Pharmaceuticals, which is expected to be immediately accretive to the ...
ANI Pharmaceuticals completes purchase of Alimera Sciences
ANI Pharmaceuticals (ANIP)  said it completed its planned acquisition of Alimera Sciences (NASDAQ:ALIM). Under the terms of ...
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a ...
ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences
PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ANIP) (“ANI” or the “Company”) announced today that the Company ...
ANI Pharmaceuticals Launches Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution
PRINCETON, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Promethazine Hydrochloride and Dextromethorphan ...